FLT3 and acute myeloid leukemia: Moreover, it was found that Lestaurtinib as a monotherapy resulted in a lessening of eruptions in both marginal blood tissues and bone marrow in about 36% of AML cases with mutated FLT3 in phase I/II clinical trials [65].